文献速递炎症性肠病

Meta分析:炎症性肠病抗TNF治疗中治疗药物监测的疗效

Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2022-12-09

该系统评价与Meta分析纳入26项研究(含9项随机对照试验),比较治疗药物监测与标准治疗或反应性监测与主动性监测,发现主动性监测较标准治疗显著降低治疗失败风险(RR 0.64),较反应性监测显著降低住院(RR 0.33)和治疗失败(RR 0.46)风险。

要点

  • 主动性治疗药物监测较标准治疗显著降低治疗失败风险(RR 0.64)。
  • 主动性监测较反应性监测显著降低住院风险(RR 0.33)和治疗失败风险(RR 0.46)。
  • 需更大规模随机对照试验和标准化检测方法进一步验证。

核心结论

  • 与标准治疗相比,主动性治疗药物监测在降低治疗失败方面具有显著获益。
  • 与反应性监测相比,主动性监测显著降低住院和治疗失败风险。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、EMBASE、EMBASE classic、PubMed、Cochrane对照试验中心注册库及Cochrane专业试验注册库,检索时间1946年1月1日至2022年4月8日。
  • 纳入随机对照试验及前瞻性和回顾性观察性研究,比较治疗药物监测与标准治疗或反应性监测与主动性监测。
  • 共纳入26项研究,其中9项为随机对照试验。

主要发现

  • 与标准治疗相比,主动性监测与治疗失败风险显著降低相关(RR 0.64,95%CI 0.48-0.85,p<0.01)。
  • 与标准治疗相比,主动性监测与手术需求(RR 0.51,95%CI 0.25-1.02)和住院(RR 0.64,95%CI 0.40-1.00)的非显著降低相关。
  • 与标准治疗相比,主动性监测与内镜缓解率(RR 1.19,95%CI 0.93-1.53)和临床缓解率(RR 1.07,95%CI 0.97-1.18)较高相关。
  • 与反应性监测相比,主动性监测与治疗失败风险显著降低相关(RR 0.46,95%CI 0.21-0.98,p=0.04)。
  • 与反应性监测相比,主动性监测与住院显著减少相关(RR 0.33,95%CI 0.21-0.54,p<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更多更大规模的随机对照试验和标准化检测方法来证实这些结果并验证治疗药物监测的成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: This systematic review and meta-analysis aimed to determine whether the use of therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients on anti-tumour necrosis factor (anti-TNF) therapy results in improved rates of clinical and endoscopic remission, surgery, corticosteroid-free remission and hospitalisation. METHODS: MEDLINE, EMBASE, EMBASE classic, PubMed, Cochrane central databases register of controlled trials and Cochrane Specialised Trials Register were searched between 01 Janurary 1946 and 08 April 2022. Randomised controlled trials (RCTs) and prospective and retrospective observational studies were included, comparing TDM to standard of care (SOC) or reactive vs proactive TDM. Results were reported as pooled relative risks (RR) with 95% confidence intervals (95% CI). RESULTS: Twenty-six studies, including 9 RCTs, were included. Compared to SOC, proactive TDM was associated with a significantly decreased risk of treatment failure (RR 0.64, 95% CI 0.48-0.85 p<0.01), and a non-significant decrease in need for surgery (RR 0.51, 95% CI 0.25-1.02) and hospitalisation (RR 0.64, 95% CI 0.40-1.00). Furthermore compared to SOC, Proactive TDM was associated with higher rates of endoscopic remission (RR 1.19, 95% CI 0.93-1.53) and clinical remission (RR 1.07, 95% CI 0.97-1.18). Compared to reactive TDM, proactive TDM was associated with significant decreased risk of treatment failure (RR 0.46, 95% CI 0.21 = 0.98, p = 0.04) and significant reduction in hospitalisation (RR 0.33, 95% CI 0.21-0.54, p < 0.01). CONCLUSIONS: Compared to SOC, proactive TDM was associated with significant benefit in reducing treatment failure. Compared to reactive TDM, proactive TDM led to a significant reduction in hospitalisation and treatment failure. More studies with larger RCTs and standardised assays are needed to substantiate these results and validate the cost-effectiveness of TDM.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sethi S, Dias S, Kumar A, et al. Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 36495020. doi:10.1111/apt.17313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。